GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mizuho Medy Co Ltd (TSE:4595) » Definitions » EBIT

Mizuho Medy Co (TSE:4595) EBIT : 円5,378 Mil (TTM As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Mizuho Medy Co EBIT?

Mizuho Medy Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was 円1,253 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was 円5,378 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Mizuho Medy Co's annualized ROC % for the quarter that ended in Mar. 2024 was 47.50%. Mizuho Medy Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 82.11%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Mizuho Medy Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 24.06%.


Mizuho Medy Co EBIT Historical Data

The historical data trend for Mizuho Medy Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mizuho Medy Co EBIT Chart

Mizuho Medy Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,172.67 417.26 6,825.76 11,104.21 5,151.99

Mizuho Medy Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,027.00 876.42 1,885.89 1,362.68 1,253.00

Competitive Comparison of Mizuho Medy Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Mizuho Medy Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mizuho Medy Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mizuho Medy Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mizuho Medy Co's EV-to-EBIT falls into.



Mizuho Medy Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円5,378 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mizuho Medy Co  (TSE:4595) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Mizuho Medy Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=5012 * ( 1 - 29.3% )/( (7036.411 + 7884)/ 2 )
=3543.484/7460.2055
=47.50 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=18948.138 - 1776.963 - ( 10134.764 - max(0, 2279.427 - 16289.781+10134.764))
=7036.411

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Mizuho Medy Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=5012/( ( (2251.446 + max(3875.59, 0)) + (2305 + max(3776, 0)) )/ 2 )
=5012/( ( 6127.036 + 6081 )/ 2 )
=5012/6104.018
=82.11 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3755.781 + 1596.608 + 802.628) - (1776.963 + 0 + 502.464)
=3875.59

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3377 + 1701 + 891) - (856 + 0 + 1337)
=3776

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Mizuho Medy Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=5377.991/22354.745
=24.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mizuho Medy Co EBIT Related Terms

Thank you for viewing the detailed overview of Mizuho Medy Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Mizuho Medy Co (TSE:4595) Business Description

Traded in Other Exchanges
N/A
Address
4 Fujinoki-Machi, Saga Prefecture, Tosu, JPN, 841-0048
Mizuho Medy Co Ltd engages in research and development, manufacture and distribution of in-vitro diagnostic products. The company provides immuno assay test products, such as influenza virus kits; Infectious diseases test kits; fecal occult blood test kits for detection of human hemoglobin and human transferrin in feces; and biochemical liquid stable reagents for professionals. It also offers HCG (midstream test), including digital p-check test for OTC. It also offers fruit tree virus test drugs to agricultural testing places.

Mizuho Medy Co (TSE:4595) Headlines

No Headlines